Supplemental Figure 1 from Phase I/Ib Study of the Efficacy and Safety of Buparlisib and Ibrutinib Therapy in MCL, FL, and DLBCL with Serial Cell-Free DNA Monitoring
Year: 2023
Type: supplementary-materials
Abstract: Supplemental Figure S1. Dosing of patients on study. A. MCL cohort. B. FL cohort. C. DLBCL cohort.
Authors: Caitlin M. Stewart, Laure Michaud, Karissa Whiting, Reiko Nakajima, Chelsea Nichols, Stephanie De Frank, Paul A. Hamlin, Matthew J. Matasar, John F. Gerecitano, Pamela Drullinsky, Audrey Hamilton, David Straus, Steven M. Horwitz, Anita Kumar, Craig H. Moskowitz, Alison Moskowitz, Andrew D. Zelenetz, Jurgen Rademaker, Gilles Salles, Venkatraman Seshan, Heiko Schöder, Anas Younes, Dana W.Y. Tsui, Connie Lee Batlevi
Language: English
Subfield: Genetics
Field: Medicine
Domain: Health Sciences
Open Access status: gold
OpenAlex ID: W4361815200